Generic Product. If during the Royalty Term, a Third Party receives marketing authorization for and commences commercial sale of a Generic Product in a country in the Territory, and quantities sold of such Generic Product represent a market share of [***] of the total market for such Generic Product and the corresponding Product sold during such Calendar Quarter in that country [***], then Bayer shall have the right to reduce any royalties payable in such country for such Product pursuant to Section 6.1 [***].
Appears in 3 contracts
Sources: Research Collaboration and Option Agreement (Recursion Pharmaceuticals, Inc.), Research Collaboration and Option Agreement (Recursion Pharmaceuticals, Inc.), Research Collaboration and Option Agreement (Recursion Pharmaceuticals, Inc.)